NxThera, Inc., a medical device company focused on providing solutions to treat endourology conditions, announced today Maximillian D. Fiore has joined the company as its Chief Development & Operations Officer. In this new role, Mr. Fiore will lead the evolution of the company’s development and operations organizations as NxThera begins to scale production and expand commercial availability of its Rezūm System to treat benign prostatic hyperplasia (BPH).
Rethink Autism was chosen by SmartCEO Magazine as a 2015 Future 50 award winner at a Hollywood-themed awards ceremony, which took place on Thursday, January 29, 2015 at Capitale.
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardio-metabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow Esperion to conduct clinical trials exceeding six months in duration.